Abstract
153Sm, a radiolanthanide of half life 46.27 h, has a gamma emission of 0.103 MeV which is well suited to imaging, it is also a moderate energy beta emitter and tumour localization of various 153Sm chelates was evaluated in B16 murine melanoma to assess their endoradiotherapeutic potential. 153Sm was prepared from enriched 152Sm in the Australian Nuclear Science and Technology Organization reactor. 153Sm chelates were prepared from 153Smchloride and their chromatographic behaviour characterized. Tumour and organ uptake of 153Sm-chloride, 153Sm-citrate and the 153Sm chelates, DTPA, HEDTA, HIDA, BZ, PBH, PIH and NTA were measured at 1, 6, 24 and 48 h after intravenous administration to C57 black mice bearing either melanotic or amelanotic B16 melanoma of mean size 0.75 cm3. Histopathological examination of the tumours at each passaging assured comparability of the degree of melanogenesis and the absence of necrosis. 153Sm-chloride was immobile on chromatography and the rapid hepatic accumulation of both 153Sm-chloride and 153Sm-citrate was attributed to in vivo formation of a colloid. In contrast, 153Sm-DTPA, moving at the solvent front on chromatography, showed no reticuloendothelial accumulation in vivo and was rapidly excreted by the kidneys without tumour uptake. The other 153Sm chelates were of intermediate stability and all localized in both melanotic and amelanotic tumours, although to a significantly lesser degree than 67Ga-citrate. The relatively high 153Sm-HIDA activity in liver and 153Sm-NTA activity in bone impaired tumour definition, but on imaging of all the 153Sm chelates only 153Sm-DTPA failed to demonstrate the B16 melanoma and the best tumour delineation was obtained using 153Sm-HEDTA.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alterman AL, Fornabaio DM, Stackpole CW (1985) Metastatic dissemination of B16 melanoma: pattern and sequence of metastasis. JNCI 75:691–699
Baker E, Vitolo ML, Webb J (1985) Iron chelation by pyridoxal isonicotinoyl hydrazone and analogues in hepatocytes in culture. Biochem Pharmacol 34:3011–3017
Brown JP, Rose TM, Plowman GD (1985) Human melanoma antigen p97, a membrane-associated transferrin homologue. In: Spik G, Montreuil J, Crichton RR, Mazurier J (eds) Proteins of iron storage and transport. Elsevier, New York, pp 39–46
Corwin LA Jr, Lattimer JC, Goeckeler WF, Stapleton J, Edwards BE, Stringham L (1986) Sm-153 EDTMP treatment of spontaneous canine bone tumours. J Nucl Med 27:986–987
Durbin PW, Williams MH, Gee M, Newman RH, Hamilton JG (1956) Metabolism of the lanthanons in the rat. Proc Soc Exp Biol Med 91:78–85
Ehrhardt GJ, Ketring AR, Volkert WA (1986) Production of Sm-153 for radiotherapeutic applications. J Labelled Comp 23:1370
Friedman AM, Sullivan JC, Ruby SL, Lindenbaum A, Russell JJ, Zabransky BJ, Rayudu GVS (1976) Studies of tumour metabolism — I: by use of Mössbauer spectroscopy and autoradiography of 153Sm. Int J Nucl Med Biol 3:37–40
Higasi T, Ito K, Tobari H, Tomura K (1973) On the accumulation of rare earth elements in animal tumour. Int J Nucl Med Biol 1:98–101
Hisada K, Ando A (1973) Radiolanthanides as promising tumour scanning agents. J Nucl Med 14:615–617
Hisada K, Ando A, Suzuki Y (1974) Radiolanthanides as tumourlocalizing agents. Proc IAEA meeting: Tumour localization with radioactive agents, IAEA — MG-50/4, Vienna, December 9–13, 1974, pp 113–122
Karika Z, Pál I, Tarján G, Füzy M, Nyul P (1972) Radioactive samarium complexes (153Sm — EDTA and 153Sm — DTPA) in medical scintigraphy. Proc IAEA symp: Medical radioisotope scintigraphy 1972 IAEA — SM-164/51, Monte Carlo, October 23–28, 1972, pp 457–465
Luk CK (1971) Study of the nature of the metal-binding sites and estimate of the distance between the metal-binding sites in transferrin using trivalent lanthanide ions as fluorescent probes. Biochemistry 10:2838–2843
Moeller T, Thomson LC (1962) The rare earths LXXV. The stabilities of diethylenetriaminepentaacetic acid chelates. J Inorg Nucl Chem 24:499–510
O'Mara RE, McAfee JG, Subramanian G (1969) Rare earth nuclides as potential agents for skeletal imaging. J Nucl Med 10:49–51
Ryan J, Cooper M, Loberg M, Harvey E, Sikorski S (1977) Technetium — 99m — labeled N-(2,6-dimethylphenylcarbamoylmethyl) iminodiacetic acid (Tc-99m HIDA): a new radiopharmaceutical for hepatobiliary imaging studies. J Nucl Med 18:997–1004
Stefansson K, Woollmann R, Jerkovic M (1982) S-100 protein in soft tissue tumours derived from Schwann cells and melanocytes. Am J Pathol 106:261–268
Sullivan JC, Friedman AM, Rayudu GVS, Fordham EW, Ramachandran PC (1975) Tumour localization studies with radioactive lanthanide and actinide complexes. Int J Nucl Med Biol 2:44–45
Turner JH, Martindale AA, de Witt C, Webb J, Sorby P, Boyd RE (1986) Tumour localization of Samarium-153 chelates in malignant melanoma. J Labelled Comp and Radiopharm 13:1367–1369
Webb J, Vitolo ML (1987) Pyridoxal isonicotinoyl hydrazone (PIH) a promising new iron chelator. In: Thalassemia: pathophysiology and management. March of Dimes Birth Defects Foundation, New York (in press)
Woolfenden JM, Hall JN, Barker HB, Wacks ME (1983) [153Sm] citrate for tumour and abscess localization. Int J Nucl Med Biol 10:251–256
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Harvey Turner, J., Martindale, A.A., Charmaine de Witt, G. et al. Samarium-153 chelate localization in malignant melanoma. Eur J Nucl Med 13, 432–438 (1987). https://doi.org/10.1007/BF00292499
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00292499